Company / Total Assets
Adaptimmune Therapeutics PLC Total Assets History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Assets
$246.0M
FY2024
5-year range
$246.0M / $469.5M
FY2020-FY2024
Trend
-13.0%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Total Assets has declined for 3 consecutive years, from $470M in FY2021 to $246M in FY2024.
Based on SEC 10-K filings.
$246M in FY2024 with a 5-year CAGR of +6.3%.
Declined from $329M to $246M over the past 2 years.
Total Assets over time
Growth rates
- 3-Year CAGR
- -19.4%
- 5-Year CAGR
- +6.3%
- 10-Year CAGR
- -
Key checks
Key Insights
- Adaptimmune Therapeutics PLC's total assets has declined for 3 consecutive years.
- 5-year CAGR of +6.3%, indicating consistent growth.
- In FY2024, total assets decreased 13.0% year-over-year.
- Peak total assets was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score -3.53 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $246.0M | -13.0% |
| FY2023 | $282.6M | -14.1% |
| FY2022 | $328.9M | -30.0% |
| FY2021 | $469.5M | +4.1% |
| FY2020 | $451.1M | +148.5% |
| FY2019 | $181.5M | -34.4% |
| FY2018 | $276.7M | -1.6% |
| FY2017 | $281.1M | +19.9% |
| FY2016 | $234.5M | - |
As of FY2024 · SEC 10-K · Updated Jun 29, 2026